|
PPID expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.89989999954676E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.40320000000072E-06 |
| Normal-vs-Stage2 |
1.836760E-03 |
| Normal-vs-Stage3 |
8.36809999960053E-07 |
| Normal-vs-Stage4 |
1.90990000481506E-08 |
| Stage1-vs-Stage2 |
7.056600E-01 |
| Stage1-vs-Stage3 |
1.208570E-01 |
| Stage1-vs-Stage4 |
1.463880E-02 |
| Stage2-vs-Stage3 |
2.023800E-01 |
| Stage2-vs-Stage4 |
3.582500E-02 |
| Stage3-vs-Stage4 |
3.066200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.06919999964816E-07 |
| Normal-vs-AfricanAmerican |
3.72539999999866E-05 |
| Normal-vs-Asian |
6.477200E-03 |
| Caucasian-vs-AfricanAmerican |
3.838800E-01 |
| Caucasian-vs-Asian |
1.421990E-01 |
| AfricanAmerican-vs-Asian |
1.064160E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.41290000038796E-07 |
| Normal-vs-Female |
7.60980000014122E-07 |
| Male-vs-Female |
6.618600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.34960000003548E-06 |
| Normal-vs-Age(41-60Yrs) |
3.43209999997818E-06 |
| Normal-vs-Age(61-80Yrs) |
4.94540000062216E-08 |
| Normal-vs-Age(81-100Yrs) |
2.520000E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.405400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.590580E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.647600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.812200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.042600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.772600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.649800E-02 |
| Classical-VS-Follicular |
4.824400E-01 |
| Classical-VS-Other |
7.929000E-01 |
| Classical-VS-Normal |
2.75330000021334E-07 |
| Tall-VS-Follicular |
2.336100E-02 |
| Tall-VS-Other |
7.714800E-01 |
| Tall-VS-Normal |
8.49269999880775E-08 |
| Follicular-VS-Other |
5.931000E-01 |
| Follicular-VS-Normal |
4.045500E-04 |
| Other-VS-Normal |
1.471760E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
8.07990000000203E-05 |
| Normal-vs-N1 |
1.74580000456004E-08 |
| N0-vs-N1 |
5.159900E-03 |
|
|
